Viking Therapeutics Receives Analyst Rating Update from Investment Bank

Viking Therapeutics (NASDAQ: VKTX) has recently gained renewed attention on Wall Street following a key rating update by a major investment bank. This development is particularly relevant for those doing stock research and monitoring the broader stock market trends in biotech. Viking Therapeutics is a clinical-stage biopharmaceutical company targeting metabolic and endocrine diseases, and its moment in the spotlight may reshape how investors view this name.